Figure 1From: Preclinical Studies in the mdx Mouse Model of Duchenne Muscular Dystrophy with the Histone Deacetylase Inhibitor GivinostatGivinostat treatment of human skeletal myoblasts increases myotube size. The myogenic potential of human skeletal myoblasts was assessed after 24 h of TSA (50 nmol/L) and givinostat (150 nmol/L) in vitro treatment. Representative images of MyHC (red) staining are shown. Nuclei were counterstained with DAPI (4′,6-diamidino-2-phenylindole; Sigma-Aldrich) (blue).Back to article page